1. Home
  2. VKTX vs WNS Comparison

VKTX vs WNS Comparison

Compare VKTX & WNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VKTX
  • WNS
  • Stock Information
  • Founded
  • VKTX 2012
  • WNS 1996
  • Country
  • VKTX United States
  • WNS India
  • Employees
  • VKTX N/A
  • WNS N/A
  • Industry
  • VKTX Biotechnology: Pharmaceutical Preparations
  • WNS Business Services
  • Sector
  • VKTX Health Care
  • WNS Consumer Discretionary
  • Exchange
  • VKTX Nasdaq
  • WNS Nasdaq
  • Market Cap
  • VKTX 3.4B
  • WNS 2.8B
  • IPO Year
  • VKTX 2015
  • WNS N/A
  • Fundamental
  • Price
  • VKTX $23.94
  • WNS $66.58
  • Analyst Decision
  • VKTX Strong Buy
  • WNS Buy
  • Analyst Count
  • VKTX 12
  • WNS 9
  • Target Price
  • VKTX $89.75
  • WNS $62.89
  • AVG Volume (30 Days)
  • VKTX 4.5M
  • WNS 821.4K
  • Earning Date
  • VKTX 04-23-2025
  • WNS 04-24-2025
  • Dividend Yield
  • VKTX N/A
  • WNS N/A
  • EPS Growth
  • VKTX N/A
  • WNS N/A
  • EPS
  • VKTX N/A
  • WNS 2.70
  • Revenue
  • VKTX N/A
  • WNS $1,315,456,000.00
  • Revenue This Year
  • VKTX N/A
  • WNS N/A
  • Revenue Next Year
  • VKTX N/A
  • WNS $7.90
  • P/E Ratio
  • VKTX N/A
  • WNS $24.68
  • Revenue Growth
  • VKTX N/A
  • WNS 1.07
  • 52 Week Low
  • VKTX $18.92
  • WNS $39.85
  • 52 Week High
  • VKTX $81.86
  • WNS $72.11
  • Technical
  • Relative Strength Index (RSI)
  • VKTX 46.06
  • WNS 58.10
  • Support Level
  • VKTX $18.92
  • WNS $58.56
  • Resistance Level
  • VKTX $27.09
  • WNS $68.18
  • Average True Range (ATR)
  • VKTX 2.31
  • WNS 4.17
  • MACD
  • VKTX 0.26
  • WNS 0.17
  • Stochastic Oscillator
  • VKTX 61.44
  • WNS 59.19

About VKTX Viking Therapeutics Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

About WNS WNS (Holdings) Limited Sponsored ADR (Jersey)

WNS (Holdings) Ltd is a Global provider of business process management (BPM) services, offering comprehensive data, voice, analytical, and business transformation services with a blended onshore, nearshore and offshore delivery model. The company's segment includes Banking/Financial Services, and Insurance; Travel, Shipping/Logistics, and Utilities; Manufacturing/Retail/Consumer, Hi-tech/Professional Services, and Procurement; Healthcare/Life Sciences. Geographically the company generates the majority of its revenue from North America (primarily the US), followed by the UK. The company also has a presence in Australia, Europe (excluding the UK), and South Africa.

Share on Social Networks: